glp-1 drugs safe from the Gray Market Research shows GLP-1 drugs are

Please see our sustainability page for more information

Thus, deficiencies in L-carnitine or its transporter CAC have particularly adverse effects on cardiomyocytes, resulting in cardiomyopathy, cardiac arrhythmia, cardiac insufficiency, and heart failure [4]

Springer, Cham, Switzerland (2018)

Case history, review of medical records and previous lab work, you may also be sent for blood work or a urine test and an IV will likely be suggested

For patients with cardiovascular disease but not chronic kidney disease, SGLT-2 inhibitors reduce overall mortality with an NNT of 39 (95% CI, 27 to 72) over five years

Evidence Summary: What the Science Actually Shows Summary: The peptide evidence base is growing but remains inconsistent